



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$9.85
Change (%)	0.00 (0.00%)
Volume	200
52 Week Low	\$2.41
Market Cap	\$396,512,558
Rolling EPS	-0.60
PE Ratio	0
Shares Outstanding	40,255,082



Data as of July 19, 2017 4:00 p.m. ET

Recent Press Releases & Upcoming Events

July 18, 2017

Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa

June 29, 2017

Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program

June 2, 2017

Abeona Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

Date	Title
September 7, 2017 through September 8, 2017	4th Annual Biopharmaceutical Research & Development Location Omaha, NE
September 12, 2017	EveryLife Foundation - "Scientific Workshop on Emerging Technologies for Rare Diseases" Location Washington, D.C.
September 14, 2017 through September 15, 2017	6th Annual RARE Patient Advocacy Summit Location Irvine, CA

SEC Filings

Filing Date	Form
May 18, 2017	8-K
May 15, 2017	10-Q
May 3, 2017	EFFECT
April 25, 2017	POS AM

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.